Project Detail
Interagency Autism Coordinating Committee (IACC) logo
Office of Autism Research Coordination (OARC) logo

Trial of a glutamate antagonist in the treatment of OCD and autistic disorders  

Riluzole, a glutamate antagonist, reduces symptoms in adults with obsessive-compulsive disorder (OCD). Preliminary data will be collected on Riluzole efficacy and safety in children and adolescents with co-morbid conditions of ASD and OCD. Project Status


Funder National Institutes of Health
Fiscal Year Funding $770,674.00
Current Award Period Ongoing
Project Number 1ZIAMH002913-03
Principal Investigator Swedo, Susan
Received ARRA Funding? No
Strategic Plan Question Question 4: Which Treatments And Interventions Will Help? (Treatments)
Subcategory Medical/Pharmacologic
Strategic Plan Objective Yellow dot: Objective has some degree of funding, but less than the recommended amount. 4LA. Complete at least three randomized controlled trials on medications targeting core symptoms in people with ASD of all ages by 2014. IACC Recommended Budget: $22,200,000 over 5 years.
Federal or Private? Federal
Institution National Institutes of Health
State/Country Maryland
Web Link 1 Trial of a glutamate antagonist in the treatment of OCD and autistic disorders (External web link)
Web Link 2 No URL available.
Web Link 3 No URL available.
New! History/Related Projects Not available at this time. This functionality is experimental.